Firebrick Pharma Limited (ASX:FRE – Get Free Report) insider Peter Molloy purchased 500,000 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were bought at an average cost of A$0.06 ($0.04) per share, with a total value of A$28,500.00 ($19,000.00).
Firebrick Pharma Price Performance
About Firebrick Pharma
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Recommended Stories
- Five stocks we like better than Firebrick Pharma
- How to Read Stock Charts for Beginners
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 5 discounted opportunities for dividend growth investors
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Firebrick Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firebrick Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
